Fortunately, the recent investigation shows the use of sodium-glucose co-transporter 2 inhibitors (SGLT2-i) was associated with a lower risk of new-onset arrhythmic events, especially VT/VF, during hospitalization and long-term follow-up for AMI patients complicated T2DM [14, 15]. The gene discussed is SLC5A2; the disease is ventricular fibrillation.